Literature DB >> 17687345

Clinical setbacks for toll-like receptor 9 agonists in cancer.

Charlie Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17687345     DOI： 10.1038/nbt0807-825

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  18 in total

1.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants.

Authors:  Sarah C Higgins; Kingston H G Mills
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

3.  Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice.

Authors:  Jun Yan; Fang Hua; Han-zhi Liu; Hong-zheng Yang; Zhuo-wei Hu
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

4.  Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination.

Authors:  Wolfgang Kratky; Caetano Reis e Sousa; Annette Oxenius; Roman Spörri
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

Review 5.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 6.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

Review 7.  Toll-like receptor agonists in cancer therapy.

Authors:  Sylvia Adams
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

8.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

9.  Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Authors:  Stefan Nierkens; Martijn H den Brok; Thijs Roelofsen; Jori A L Wagenaars; Carl G Figdor; Theo J Ruers; Gosse J Adema
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

Review 10.  Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis: what is new?

Authors:  Yvonne Vercoulen; Nienke H van Teijlingen; Ismé M de Kleer; Sylvia Kamphuis; Salvatore Albani; Berent J Prakken
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.